Cargando…

Development of flavivirus subviral particles with low cross-reactivity by mutations of a distinct antigenic domain

ABSTRACT: The most conserved fusion loop (FL) domain present in the flavivirus envelope protein has been reported as a dominant epitope for cross-reactive antibodies to mosquito-borne flaviviruses (MBFVs). As a result, establishing accurate serodiagnosis for MBFV infections has been difficult as ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Tabata, Koshiro, Itakura, Yukari, Ariizumi, Takuma, Igarashi, Manabu, Kobayashi, Hiroko, Intaruck, Kittiya, Kishimoto, Mai, Kobayashi, Shintaro, Hall, William W., Sasaki, Michihito, Sawa, Hirofumi, Orba, Yasuko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656323/
https://www.ncbi.nlm.nih.gov/pubmed/37831184
http://dx.doi.org/10.1007/s00253-023-12817-5
_version_ 1785136988580478976
author Tabata, Koshiro
Itakura, Yukari
Ariizumi, Takuma
Igarashi, Manabu
Kobayashi, Hiroko
Intaruck, Kittiya
Kishimoto, Mai
Kobayashi, Shintaro
Hall, William W.
Sasaki, Michihito
Sawa, Hirofumi
Orba, Yasuko
author_facet Tabata, Koshiro
Itakura, Yukari
Ariizumi, Takuma
Igarashi, Manabu
Kobayashi, Hiroko
Intaruck, Kittiya
Kishimoto, Mai
Kobayashi, Shintaro
Hall, William W.
Sasaki, Michihito
Sawa, Hirofumi
Orba, Yasuko
author_sort Tabata, Koshiro
collection PubMed
description ABSTRACT: The most conserved fusion loop (FL) domain present in the flavivirus envelope protein has been reported as a dominant epitope for cross-reactive antibodies to mosquito-borne flaviviruses (MBFVs). As a result, establishing accurate serodiagnosis for MBFV infections has been difficult as anti-FL antibodies are induced by both natural infection and following vaccination. In this study, we modified the most conserved FL domain to overcome this cross-reactivity. We showed that the FL domain of lineage I insect-specific flavivirus (ISFV) has differences in antigenicity from those of MBFVs and lineage II ISFV and determined the key amino acid residues (G106, L107, or F108), which contribute to the antigenic difference. These mutations were subsequently introduced into subviral particles (SVPs) of dengue virus type 2 (DENV2), Zika virus (ZIKV), Japanese encephalitis virus (JEV), and West Nile virus (WNV). In indirect enzyme-linked immunosorbent assays (ELISAs), these SVP mutants when used as antigens reduced the binding of cross-reactive IgG and total Ig induced by infection of ZIKV, JEV, and WNV in mice and enabled the sensitive detection of virus-specific antibodies. Furthermore, immunization of ZIKV or JEV SVP mutants provoked the production of antibodies with lower cross-reactivity to heterologous MBFV antigens compared to immunization with the wild-type SVPs in mice. This study highlights the effectiveness of introducing mutations in the FL domain in MBFV SVPs with lineage I ISFV-derived amino acids to produce SVP antigens with low cross-reactivity and demonstrates an improvement in the accuracy of indirect ELISA-based serodiagnosis for MBFV infections. KEY POINTS: • The FL domain of Lineage I ISFV has a different antigenicity from that of MBFVs. • Mutated SVPs reduce the binding of cross-reactive antibodies in indirect ELISAs. • Inoculation of mutated SVPs induces antibodies with low cross-reactivity. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00253-023-12817-5.
format Online
Article
Text
id pubmed-10656323
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-106563232023-10-13 Development of flavivirus subviral particles with low cross-reactivity by mutations of a distinct antigenic domain Tabata, Koshiro Itakura, Yukari Ariizumi, Takuma Igarashi, Manabu Kobayashi, Hiroko Intaruck, Kittiya Kishimoto, Mai Kobayashi, Shintaro Hall, William W. Sasaki, Michihito Sawa, Hirofumi Orba, Yasuko Appl Microbiol Biotechnol Applied Genetics and Molecular Biotechnology ABSTRACT: The most conserved fusion loop (FL) domain present in the flavivirus envelope protein has been reported as a dominant epitope for cross-reactive antibodies to mosquito-borne flaviviruses (MBFVs). As a result, establishing accurate serodiagnosis for MBFV infections has been difficult as anti-FL antibodies are induced by both natural infection and following vaccination. In this study, we modified the most conserved FL domain to overcome this cross-reactivity. We showed that the FL domain of lineage I insect-specific flavivirus (ISFV) has differences in antigenicity from those of MBFVs and lineage II ISFV and determined the key amino acid residues (G106, L107, or F108), which contribute to the antigenic difference. These mutations were subsequently introduced into subviral particles (SVPs) of dengue virus type 2 (DENV2), Zika virus (ZIKV), Japanese encephalitis virus (JEV), and West Nile virus (WNV). In indirect enzyme-linked immunosorbent assays (ELISAs), these SVP mutants when used as antigens reduced the binding of cross-reactive IgG and total Ig induced by infection of ZIKV, JEV, and WNV in mice and enabled the sensitive detection of virus-specific antibodies. Furthermore, immunization of ZIKV or JEV SVP mutants provoked the production of antibodies with lower cross-reactivity to heterologous MBFV antigens compared to immunization with the wild-type SVPs in mice. This study highlights the effectiveness of introducing mutations in the FL domain in MBFV SVPs with lineage I ISFV-derived amino acids to produce SVP antigens with low cross-reactivity and demonstrates an improvement in the accuracy of indirect ELISA-based serodiagnosis for MBFV infections. KEY POINTS: • The FL domain of Lineage I ISFV has a different antigenicity from that of MBFVs. • Mutated SVPs reduce the binding of cross-reactive antibodies in indirect ELISAs. • Inoculation of mutated SVPs induces antibodies with low cross-reactivity. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00253-023-12817-5. Springer Berlin Heidelberg 2023-10-13 2023 /pmc/articles/PMC10656323/ /pubmed/37831184 http://dx.doi.org/10.1007/s00253-023-12817-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Applied Genetics and Molecular Biotechnology
Tabata, Koshiro
Itakura, Yukari
Ariizumi, Takuma
Igarashi, Manabu
Kobayashi, Hiroko
Intaruck, Kittiya
Kishimoto, Mai
Kobayashi, Shintaro
Hall, William W.
Sasaki, Michihito
Sawa, Hirofumi
Orba, Yasuko
Development of flavivirus subviral particles with low cross-reactivity by mutations of a distinct antigenic domain
title Development of flavivirus subviral particles with low cross-reactivity by mutations of a distinct antigenic domain
title_full Development of flavivirus subviral particles with low cross-reactivity by mutations of a distinct antigenic domain
title_fullStr Development of flavivirus subviral particles with low cross-reactivity by mutations of a distinct antigenic domain
title_full_unstemmed Development of flavivirus subviral particles with low cross-reactivity by mutations of a distinct antigenic domain
title_short Development of flavivirus subviral particles with low cross-reactivity by mutations of a distinct antigenic domain
title_sort development of flavivirus subviral particles with low cross-reactivity by mutations of a distinct antigenic domain
topic Applied Genetics and Molecular Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656323/
https://www.ncbi.nlm.nih.gov/pubmed/37831184
http://dx.doi.org/10.1007/s00253-023-12817-5
work_keys_str_mv AT tabatakoshiro developmentofflavivirussubviralparticleswithlowcrossreactivitybymutationsofadistinctantigenicdomain
AT itakurayukari developmentofflavivirussubviralparticleswithlowcrossreactivitybymutationsofadistinctantigenicdomain
AT ariizumitakuma developmentofflavivirussubviralparticleswithlowcrossreactivitybymutationsofadistinctantigenicdomain
AT igarashimanabu developmentofflavivirussubviralparticleswithlowcrossreactivitybymutationsofadistinctantigenicdomain
AT kobayashihiroko developmentofflavivirussubviralparticleswithlowcrossreactivitybymutationsofadistinctantigenicdomain
AT intaruckkittiya developmentofflavivirussubviralparticleswithlowcrossreactivitybymutationsofadistinctantigenicdomain
AT kishimotomai developmentofflavivirussubviralparticleswithlowcrossreactivitybymutationsofadistinctantigenicdomain
AT kobayashishintaro developmentofflavivirussubviralparticleswithlowcrossreactivitybymutationsofadistinctantigenicdomain
AT hallwilliamw developmentofflavivirussubviralparticleswithlowcrossreactivitybymutationsofadistinctantigenicdomain
AT sasakimichihito developmentofflavivirussubviralparticleswithlowcrossreactivitybymutationsofadistinctantigenicdomain
AT sawahirofumi developmentofflavivirussubviralparticleswithlowcrossreactivitybymutationsofadistinctantigenicdomain
AT orbayasuko developmentofflavivirussubviralparticleswithlowcrossreactivitybymutationsofadistinctantigenicdomain